- Home
- LRHC vs KPRX Comparison
LRHC vs KPRX Comparison
Compare LRHC & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRHC
- KPRX
- Stock Information
- Founded
- LRHC 2004
- KPRX 1998
- Country
- LRHC United States
- KPRX United States
- Employees
- LRHC N/A
- KPRX N/A
- Industry
- LRHC
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LRHC
- KPRX Health Care
- Exchange
- LRHC Nasdaq
- KPRX Nasdaq
- Market Cap
- LRHC 8.4M
- KPRX 9.2M
- IPO Year
- LRHC 2023
- KPRX N/A
- Fundamental
- Price
- LRHC $5.42
- KPRX $2.51
- Analyst Decision
- LRHC
- KPRX Strong Buy
- Analyst Count
- LRHC 0
- KPRX 1
- Target Price
- LRHC N/A
- KPRX $10.00
- AVG Volume (30 Days)
- LRHC 10.6K
- KPRX 52.9K
- Earning Date
- LRHC 11-19-2025
- KPRX 11-07-2025
- Dividend Yield
- LRHC N/A
- KPRX N/A
- EPS Growth
- LRHC N/A
- KPRX N/A
- EPS
- LRHC N/A
- KPRX N/A
- Revenue
- LRHC $78,037,079.00
- KPRX N/A
- Revenue This Year
- LRHC N/A
- KPRX N/A
- Revenue Next Year
- LRHC N/A
- KPRX N/A
- P/E Ratio
- LRHC N/A
- KPRX N/A
- Revenue Growth
- LRHC 54.92
- KPRX N/A
- 52 Week Low
- LRHC $4.33
- KPRX $2.21
- 52 Week High
- LRHC $142.40
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- LRHC 31.93
- KPRX 43.08
- Support Level
- LRHC $5.00
- KPRX $2.21
- Resistance Level
- LRHC $7.04
- KPRX $2.80
- Average True Range (ATR)
- LRHC 0.42
- KPRX 0.15
- MACD
- LRHC -0.22
- KPRX -0.03
- Stochastic Oscillator
- LRHC 15.85
- KPRX 43.24
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.